Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients

Journal of Nuclear Medicine

Volumn 49, Issue 6, 2008, Pages 879-886

  Kenny, Laura M ^a   Coombes, R Charles ^a   Oulie, Inger ^b   Contractor, Kaiyumars B ^a   Miller, Matthew ^b   Spinks, Terence J ^a   McParland, Brian ^b   Cohen, Pamela S ^b   Hui, Ai Min ^b   Palmieri, Carlo ^a   Osman, Safiye ^b   Glaser, Matthias ^b   Turton, David ^b   Al Nahhas, Adil ^a   Aboagye, Eric O ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b GE HEALTHCARE   (United Kingdom)

Author keywords

v 3; Integrin; Positron emission tomography; RGD; Tumor

Indexed keywords

AH 111585; AH 111585 F 18; ARGINYLGLYCYLASPARTIC ACID; RADIOLIGAND;

ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DISTRIBUTION; DRUG SAFETY; DRUG STABILITY; DRUG TOLERANCE; HUMAN; HUMAN TISSUE; PHASE 1 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; HUMANS; METABOLIC CLEARANCE RATE; MIDDLE AGED; OLIGOPEPTIDES; ORGAN SPECIFICITY; PEPTIDES; POLYETHYLENE GLYCOLS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 44849137859     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.107.049452     Document Type: Article

References (33)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
2. Brooks PC. Role of integrins in angiogenesis. Eur J Cancer. 1996;32A:2423-2429.
3. Giancotti FG, Ruoslahti E. Integrin signaling. Science. 1999;285:1028-1032.
4. Albelda SM, Mette SA, Elder DE, et al. Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression. Cancer Res. 1990;50:6757-6764.
5. Bello L, Francolini M, Marthyn P, et al. Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. Neurosurgery. 2001;49:380-389.
6. Gasparini G, Brooks PC, Biganzoli E, et al. Vascular integrin alpha(v)beta3: a new prognostic indicator in breast cancer. Clin Cancer Res. 1998;4:2625-2634.
7. Sengupta S, Chattopadhyay N, Ray S, Mitra A, Dasgupta S, Chatterjee A. Role of aphavbeta3 integrin receptor in breast tumor. J Exp Clin Cancer Res. 2001;20:203-208.
8. Zitzmann S, Ehemann V, Schwab M. Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor endothelial cells in vivo. Cancer Res. 2002;62:5139-5143.
9. 18F]galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer Res. 2006;12:3942-3949.
10. 18F]galacto-RGD. PLoS Med. 2005;2:e70.
11. Koivunen E, Wang B, Ruoslahti E. Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Biotechnology (NY). 1995;13:265-270.
12. Indrevoll B, Kindberg GM, Solbakken M, et al. NC-100717: a versatile RGD peptide scaffold for angiogenesis imaging. Bioorg Med Chem Lett. 2006;16:6190-6193.
13. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655.
14. 18F-fluorinated aldehyde-containing prosthetic groups. Bioconjug Chem. Mar. 15, 2008 [Epub ahead of print].
15. 18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. Cancer Res. 2005;65:10104-10112.
16. Mankoff DA, Shields AF, Graham MM, Link JM, Krohn KA. A graphical analysis method to estimate blood-to-tissue transfer constants for tracers with labeled metabolites. J Nucl Med. 1996;37:2049-2057.
17. Cunningham VJ, Jones T. Spectral analysis of dynamic PET studies. J Cereb Blood Flow Metab. 1993;13:15-23.
18. 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression. J Nucl Med. 2006;47:763-769.
19. Haubner R, Wester HJ, Burkhart F, et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med. 2001;42:326-336.
20. 99mTc- labeled cyclic RGD tetramer for non-invasive imaging integrin αvβ3-positive breast cancer. Bioconjug Chem. 2007;18:438-446.
21. Wester HJ, Kessler H. Molecular targeting with peptides or peptide-polymer conjugates: just a question of size? J Nucl Med. 2005;46:1940-1945.
22. 64Cu-labeled tetrameric RGD peptide. J Nucl Med. 2005;46:1707-1718.
23. Fox SB, Leek RD, Weekes MP, Whitehouse RM, Gatter KC, Harris AL. Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. J Pathol. 1995;177:275-283.
24. Fox SB, Turner GD, Leek RD, Whitehouse RM, Gatter KC, Harris AL. The prognostic value of quantitative angiogenesis in breast cancer and role of adhesion molecule expression in tumor endothelium. Breast Cancer Res Treat. 1995;36:219-216.
25. Koukourakis MI, Giatromanolaki A, Sivridis E, Fezoulidis I. Cancer vascularization: implications in radiotherapy. Int J Radiat Oncol Biol Phys. 2000;48:545-553.
26. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast cancer. J Natl Cancer Inst. 1992;84:1875-1887.
27. 3. Bio Techniques. 2005;39(suppl):S6-S17.
28. Stessels F, Van den Eynden G, Van der Auwera I, et al. Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia. Br J Cancer. 2004;90:1429-1436.
29. 18F]galacto-RGD positron emission tomography for imaging of αvβ3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res. 2007;13:6610-6616.
30. Pasqualini R, Koivunen E, Ruoslahti E. Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol. 1997;15:542-546.
31. Ṕecheur I, Peyruchaud O, Serre CM, et al. Integrin alpha(v)beta3 expression confers on tumor cells a greater propensity to metastasize to bone. FASEB J. 2002;16:1266-1268.
32. Miller JC, Pien HH, Sahani D, Sorensen AG, Thrall JH. Imaging angiogenesis: applications and potential fordrug development. J Natl Cancer Inst. 2005;97:172-187.
33. 18F labeled angiogenesis imaging agent. 2007 ASCO Annual Meeting Proceedings. J Clin Oncol. 2007;25:10507.